Novartis challenges court ruling allowing use of Avastin in wet AMDNovartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Share XNovartis challenges court ruling allowing use of Avastin in wet AMDhttps://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/
Deep Lens unveils cancer diagnosis AI tech for pathologistsDigital pathology startup Deep Lens has unveiled an artificial intelligence (AI) platform that will enable pathologists to diagnose Share XDeep Lens unveils cancer diagnosis AI tech for pathologistshttps://pharmaphorum.com/news/deep-lens-unveils-cancer-diagnosis-ai-tech-for-pathologists/
Novo Nordisk poaches AZ’s Helfgott to run Biopharm businessNovo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia Share XNovo Nordisk poaches AZ’s Helfgott to run Biopharm businesshttps://pharmaphorum.com/news/novo-nordisk-poaches-azs-helfgott-to-run-biopharm-business/
Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
BMS Opdivo fails in small cell lung cancerBristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with Share XBMS Opdivo fails in small cell lung cancerhttps://pharmaphorum.com/news/bms-opdivo-fails-in-small-cell-lung-cancer/
BMS invests $12m in cancer immunotherapy tie-up with CompugenBristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could Share XBMS invests $12m in cancer immunotherapy tie-up with Compugenhttps://pharmaphorum.com/news/bms-invests-12m-in-cancer-immunotherapy-tie-up-with-compugen/
Allogene astounds Wall Street with $324m IPO to fund cell therapy R&DGreat things were expected of Allogene Therapeutics’ IPO this week – the company is led by Arie Belldegrun Share XAllogene astounds Wall Street with $324m IPO to fund cell therapy R&Dhttps://pharmaphorum.com/news/allogene-astounds-wall-street-with-324m-ipo-to-fund-cell-therapy-rd/
Sandoz free to launch Humira biosimilar following AbbVie dealNovartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) Share XSandoz free to launch Humira biosimilar following AbbVie dealhttps://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/
Ionis and Roche to develop RNAi AMD drug in $760m dealIonis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug Share XIonis and Roche to develop RNAi AMD drug in $760m dealhttps://pharmaphorum.com/news/ionis-and-roche-to-develop-rnai-amd-drug-in-760m-deal/
